Arcutis BiotherapeuticsARQT
ARQT
About: Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
Employees: 342
0
Funds holding %
of 7,372 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
107% more call options, than puts
Call options by funds: $8.22M | Put options by funds: $3.96M
71% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 28
50% more funds holding in top 10
Funds holding in top 10: 4 [Q3] → 6 (+2) [Q4]
48% more capital invested
Capital invested by funds: $1.21B [Q3] → $1.79B (+$585M) [Q4]
10% more funds holding
Funds holding: 187 [Q3] → 206 (+19) [Q4]
0.96% less ownership
Funds ownership: 111.01% [Q3] → 110.06% (-0.96%) [Q4]
12% less repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 66
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$15
1%
upside
Avg. target
$18.80
26%
upside
High target
$21
41%
upside
5 analyst ratings
4 positive
80%
1 neutral
20%
0 negative
0%
Jefferies Kambiz Yazdi 20% 1-year accuracy 1 / 5 met price target | 28%upside $19 | Buy Maintained | 11 Mar 2025 |
Goldman Sachs Jonathan Block 20% 1-year accuracy 4 / 20 met price target | 1%upside $15 | Neutral Maintained | 27 Feb 2025 |
HC Wainwright & Co. Douglas Tsao 25% 1-year accuracy 45 / 180 met price target | 28%upside $19 | Buy Reiterated | 26 Feb 2025 |
Mizuho Uy Ear 50% 1-year accuracy 3 / 6 met price target | 41%upside $21 | Outperform Maintained | 26 Feb 2025 |
Needham Serge Belanger 48% 1-year accuracy 59 / 123 met price target | 34%upside $20 | Buy Reiterated | 26 Feb 2025 |
Financial journalist opinion
Based on 17 articles about ARQT published over the past 30 days
Positive
Zacks Investment Research
1 day ago
Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year?
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Benitec Biopharma Limited (BNTC) have performed compared to their sector so far this year.
Neutral
GlobeNewsWire
6 days ago
Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting
Data demonstrated favorable safety and local tolerability of ZORYVE® (roflumilast) cream 0.15% in adults and children with atopic dermatitis (AD) with prior inadequate response, intolerance, and contraindications to topical treatments New patient reported outcome data for investigational ZORYVE® (roflumilast) foam 0.3% demonstrated favorable efficacy, safety, and local tolerability data in scalp and body psoriasis In the United States, AD affects approximately 26 million adults and children and psoriasis affects approximately 9 million adults and children, with more than half experiencing involvement of the scalp WESTLAKE VILLAGE, Calif. and ORLANDO, Fla.
Positive
Zacks Investment Research
1 week ago
Arcutis Biotherapeutics, Inc. (ARQT) Just Overtook the 50-Day Moving Average
From a technical perspective, Arcutis Biotherapeutics, Inc. (ARQT) is looking like an interesting pick, as it just reached a key level of support. ARQT recently overtook the 50-day moving average, and this suggests a short-term bullish trend.
Neutral
GlobeNewsWire
1 week ago
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 27,000 restricted stock units of Arcutis' common stock to three newly hired employees. These awards were approved by the Compensation Committee of Arcutis' Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of March 3, 2025, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).
Positive
Zacks Investment Research
1 week ago
Wall Street Analysts See a 48.36% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 48.4% in Arcutis Biotherapeutics (ARQT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Neutral
GlobeNewsWire
1 week ago
Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting
One poster will share pooled INTEGUMENT data of ZORYVE® (roflumilast) cream 0.15% in atopic dermatitis (AD) in patients with prior inadequate response, intolerance, and/or contraindications to topical treatments including topical steroids Second poster will highlight improvements in patient-related outcomes with ZORYVE® (roflumilast) foam 0.3% in psoriasis of the scalp and body WESTLAKE VILLAGE, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will present two posters at the 2025 American Academy of Dermatology (AAD) annual meeting which will take place in Orlando, FL, from March 7 – 11, 2025.
Positive
Seeking Alpha
2 weeks ago
Arcutis: ZORYVE Net Product Revenue Growth Isn't The Only Opportunity On Deck
Data from phase 1b study, using ARQ-255 for the treatment of patients with alopecia areata, expected in the 1st half of 2025. The global alopecia areata market size is expected to be worth $6.92 billion by 2034. Full-year 2024 net product revenue of ZORYVE was $166.5 million, which was a year-over-year growth rate of 471%.
Positive
Seeking Alpha
2 weeks ago
Arcutis Biotherapeutics: Reiterating Strong Buy As Q4 Results Top Expectations
Arcutis Biotherapeutics is a strong buy due to ZORYVE's rapid sales growth and potential for positive earnings within 12 months. ZORYVE, a non-steroidal cream for psoriasis and dermatitis, saw Q4 sales of $69.4M, a 413% YoY increase, beating sales estimates by $10.8M. ZORYVE has maintained quarterly growth of >40% since Q1 2024. Remarkably only one additional quarter of such robust growth will bring sales to a pace needed to achieve profitability.
Neutral
GlobeNewsWire
2 weeks ago
U.S. FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of October 13, 2025 Application supported by positive efficacy and safety data from pivotal Phase 3 trial, pivotal long-term extension study, and Phase 1 pharmacokinetic study If approved, ZORYVE cream 0.05% will be a new topical therapy option for approximately 1.8 million children aged 2 to 5 with atopic dermatitis (AD) in the United States WESTLAKE VILLAGE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the FDA's acceptance of a supplemental New Drug Application (sNDA) for ZORYVE (roflumilast) cream 0.05%, a once-daily, next generation phosphodiesterase-4 (PDE4) inhibitor, for the topical treatment of mild to moderate AD in children 2 to 5 years old.
Neutral
Seeking Alpha
2 weeks ago
Arcutis Biotherapeutics, Inc. (ARQT) Q4 2024 Earnings Call Transcript
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT ) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET Company Participants Latha Vairavan - Vice President, Finance & Investor Relations Frank Watanabe - President & Chief Executive Officer Todd Edwards - Chief Commercial Officer Patrick Burnett - Chief Medical Officer David Topper - Chief Financial Officer Conference Call Participants Vikram Purohit - Morgan Stanley Tyler Van Buren - TD Cowen Seamus Fernandez - Guggenheim Securities Serge Belanger - Needham & Co. Uy Ear - Mizuho Kambiz Yazdi - Jefferies Douglas Tsao - H.C. Wainwright Operator Good day and welcome to Arcutis Biotherapeutics 2024 Fourth Quarter and Full Year Financial Results Conference Call.
Charts implemented using Lightweight Charts™